Background: High-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is the standard of care for patients with relapsed Hodgkin's lymphoma (HL). However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT.
introduction
Hodgkin's lymphoma (HL) is a potentially curable disease with standard chemotherapy combinations. For patients failing firstline treatment, high-dose chemotherapy followed by autologous stem cell transplantation (ASCT) is currently considered the standard of care [1] . Although sustained remissions after ASCT have been reported, 40%-50% of the patients will have recurrence of the disease. Therapeutic options are very heterogeneous and include salvage chemotherapy and/or radiotherapy followed or not by a second stem cell transplantation (autologous or allogeneic), palliative care, new drugs, or biological agents [2] . In the last years, there is increasing evidence of a clinical benefit of allogeneic transplantation using reduced intensity conditioning regimens † (alloRIC) [3] [4] [5] . Identification of prognostic factors in these patients need to be redefined, specially in the era of allogeneic transplant and new drugs, for an adequate patient selection for different salvage treatments.
A number of variables present at the time of first relapse of HL or immediately before ASCT have been evaluated with regard to their influence on risk of relapse following transplantation [6] [7] [8] [9] [10] . However, there is currently little information on the predictors of outcome for patients whose disease recurs after ASCT.
The present study is intended to analyze prognostic factors, management, and outcome of patients with HL relapsing after ASCT using the European Group for Blood and Marrow Transplantation (EBMT) and the Gruppo Italiano Trapianto di Midollo Osseo (GITMO) databases.
methods patients and definitions
Between January 1996 and November 2005, a total of 2200 patients with HL and ≥18 years old were reported to the EBMT registry as having disease relapse/progression after a first ASCT. Patients undergoing planned tandem autologous transplants were not included in the study. Informed consent was obtained locally according to regulations applicable at the time of transplantation and EBMT policy. Data for this study were obtained from the lymphoma registry files (minimal essential data Med-A form) and extended by a specific questionnaire (Med-C form) sent to all participant transplantation centers to obtain data regarding characteristics of the patients and outcome after ASCT failure. Data from Italian centers were previously reported to the GITMO database, and then added to the general EBMT collected data. A total of 511 patients had a completed Med-C form.
statistical analysis
The probability of overall survival (OS) was estimated from the time of relapse after the ASCT according to the Kaplan-Meier method. The variables examined in univariate analysis were sex, age, number of treatment-lines before ASCT (1-2 versus ≥3), time from ASCT to relapse/ progression (<6 versus ≥6 months), histological classification, Ann Arbor stage, B symptoms, bulky disease, extranodal involvement, and performance status (PS). The two-tailed log-rank test was used to compare differences in survival for each factor. Cox proportional hazards models were built to determine whether the identified risk factors independently influenced OS. We tested the proportional hazards assumption for each factor in the Cox model using time-dependent covariates. Risk groups were defined by comparing OS of patients with each possible number of presenting risk factors. Then, categories were combined according to their prognosis value and the number of patients within each category, to produce a score index with the best discriminating power.
To compare outcome of patients treated with chemotherapy/radiotherapy versus alloRIC, statistical analyses were carried out introducing alloRIC as a time-dependent covariate.
For data analysis, computer-based Statistical Package for Social Sciences for Windows, version 15 (SPSS, Inc., Chicago, IL) was used. All P-values reported are two sided, and statistical significance was defined as P < 0.05.
results
No differences were observed in OS from ASCT failure between patients included (n = 511) and those fulfilling the same inclusion criteria but not included (n = 1689) in the study (39.6% versus 37.9% at 3 years, respectively; P > 0.5), indicating that the data provided by this study are representative of the entire group of patients. Forty-nine of 511 patients received only palliative care with a median OS of only 2.6 months. This subgroup of patients was excluded from the final analysis that was carried out in a total of 462 patients ( Figure 1 , Supplementary material, available at Annals of Oncology online).
characteristics of the patients
Median age was 31 (range, 18-72) years at the time of ASCT. Adverse features such as Ann Arbor stage III-IV, B symptoms, and bulky disease were present in 67%, 49%, and 7% of the patients. Thirty-one percent of patients were in complete remission, 54% had sensitive disease and 15% had refractory HL. Median time from diagnosis to ASCT was 21 (range, 5-244) months. Details regarding characteristics of the patients at the time of ASCT failure are provided in Table 1 . The median interval from ASCT to treatment failure was 7 (1-78) months.
treatment after ASCT failure
Treatments administered following ASCT failure included conventional chemotherapy/radiotherapy in 294 (64%) patients, second ASCT in 35 (8%), and alloSCT in 133 (29%). Most alloSCT (78%) were alloRIC. Eighty-five (64%) patients received alloSCT within the first year after ASCT failure. A significant higher number of patients <50 years old were treated with a second transplantation in comparison with older patients (39% versus 16%, respectively, P = 0.006).
overall survival from ASCT failure One hundred and fifty-five (33.5%) of the 462 patients are currently alive, with a median follow-up for surviving patients of 49 (range, 1-150) months. The median survival from ASCT failure was 29 months with an OS of 55% (95% CI 35-44) at 2 years and 32% (95% CI 25-34) at 5 years ( Figure 1 ). In univariate analysis of survival, poorer prognosis was associated with relapse within the first 6 months after ASCT (P < 0.001), Figure 1 . OS from ASCT failure.
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stage IV (P < 0.001), the presence of B symptoms (P < 0.001), the presence of bulky disease (P < 0.001), extranodal involvement (P < 0.001), and PS under 80% (P < 0.001). Sex and age were also included in the multivariate analysis as variables with potential clinical impact. The risk factors that remained independently significant in multivariate analysis were early relapse [relative risk (RR) 1.5, 95% confidence interval (CI) 1.2-1.9, P < 0.001], stage IV (RR 1.6, 95% CI 1.6-2.1, P = 0.001), bulky disease (RR 1.8, 95% CI 1.1-3.0, P = 0.044), poor PS (RR 3.2, 95% CI 2.3-4.4, P < 0.001), and age ≥50 years old (RR 1.5, 95% CI 1.1-2.3, P = 0.019). We therefore attempted to combine relevant factors into a single prognostic score. Three risk groups were created by identifying patients who had 0, 1, or 2 or more adverse factors. These groups had significantly different OS, from 62% (95% CI 48-75) at 5 years for those patients with no adverse factors, 37% (95% CI 25-49) for those with 1 factor, and 12% (95% CI 6-18) for those with ≥2 (Figure 2 ). Patients with different prognostic score were equally distributed into the different treatment groups. The prognostic score was also predictive for OS independently of the type of treatment administered after ASCT failure. Thus, OS for those patients treated with chemotherapy/radiotherapy and with no adverse factors was of 61% (95% CI 44-78) at 5 years in comparison with 39% (95% CI 25-52) and 10% (95% CI 3-16) for those having 1 or ≥2 factors, respectively (P < 0.0001). OS for patients treated with alloSCT and with no risk factors was 59% (95% CI 33-84) at 5 years in comparison with 29% (95% CI 5-52) and 28% (95% CI 15-41) for those having 1 or ≥2 factors, respectively (P = 0.058). The number of patients treated with a second ASCT was too low to apply the prognostic score.
chemotherapy/radiotherapy versus alloRIC
Patients were offered salvage treatment followed or not by second transplantation at different times after ASCT failure. In order to ensure the comparability of the groups regarding salvage treatment options and follow-up, this analysis was restricted to patients who received ASCT in the period of 2000-2005. A total of 195 patients were treated with chemotherapy/radiotherapy and 49 received an alloRIC. There were no statistical differences in sex, histological HL subtype, time from ASCT to relapse, stage of HL, presence of B symptoms, bulky disease, extranodal involvement at ASCT, or PS at relapse between groups. Details regarding alloRIC procedure are provided in Supplementary Table S1, available at Annals of Oncology online. Estimated non-relapse mortality and cumulative incidence of relapse were 10% and 61% at 2 years, respectively. OS at 4 years from ASCT failure was 48% for patients receiving alloRIC and 32% for those treated with conventional chemotherapy/radiotherapy with a median survival time of 45 and 19 months, respectively (Supplementary Figure S2 , available at Annals of Oncology online). In multivariate analysis, alloRIC was associated with a trend to an improved survival (P = 0.08).
discussion
In this analysis, we have described the largest series of patients with HL progressing after ASCT reported to date and have identified clinical parameters at the time of relapse predicting long-term outcome.
This and other studies have shown that relapse after ASCT does not necessarily lead to immediate death [11] [12] [13] [14] . Although a previous series showed a median survival time after ASCT failure of 10.5 months, more recent reports and our results indicate that survival may be longer, with a median of 25-32 months [11] [12] [13] [14] . This difference could be a reflection of changes original articles Annals of Oncology in the management of HL disease and improvement of supportive care along the last decades. Thus, patients undergone ASCT earlier in the course of their disease and a higher proportion of patients is treated with a second SCT after ASCT failure. In our study, early relapse was associated with poor outcome. The median time from ASCT to therapy failure was 7 months. OS at 5 years for patients relapsing within 6 months of ASCT failure was 25% versus 40% for those with later HL progression. This is in agreement with recent reports showing a median time of progression of 5-6 months and a significant impact of early relapse on OS and progression-free survival [11] [12] [13] [14] . This could be explained, at least in part, by the fact that patients with early relapse could not be considered for potentially curative therapies such as alloSCT. However, early relapse has also been reported as an independent factor for poor outcome in patients treated with alloRIC. In the study by Moskowitz et al., a total of 19 of 71 patients with HL progressing after ASCT proceeded to alloRIC [12] . Of them, all patients who relapsed within 6 months died of progression of disease or graft-versus-host disease. This result is consistent with data reported by the EBMT which included 285 patients [15] . In this series, relapse within 6 months of a prior ASCT was associated with a higher relapse rate and a lower progression-free survival. In our study, early relapse was associated not only with poor prognosis in those patients treated with alloSCT, but also in those treated with chemotherapy/radiotherapy without a second transplantation. Then, it is possible that prolonged time to relapse is indicative of a less aggressive disease that is amenable to treatment with several options included alloRIC but also with chemotherapy/radiotherapy or novel agents followed or not by a second SCT.
Regarding other prognostic factors, we found that stage IV, bulky disease, age ≥50 years, and poor PS were associated with poor outcome. This result was not surprising since these factors have also been reported as predictive for outcome when they are analyzed at the time of diagnosis of HL, at relapse, or before transplantation. Stage IV and age ≥45, together with hypoalbuminemia, anemia, male sex, leukocytosis, and lymphocytopenia, were significant prognostic factors for freedom from disease progression in the international prognostic score for newly diagnosed advanced stage HL patients [16] . In 2002, the German Hodgkin Study Group developed a new prognostic score based on treatment outcome of patients with relapsed HL in which, clinical stage at relapse was one of the independent risk factors for OS [9] . In another analysis from the same group regarding prognostic factors and treatment outcome in primary progressive HL patients, low Karnofsky PS and age >50 years had an adverse impact on OS [8] . Advanced stage HL and B symptoms before ASCT were also shown to adversely affect outcome [10] . In the setting of alloRIC, poor PS and age >45 have also been associated with higher nonrelapse mortality and worse OS after transplantation [15] .
In our study, alloRIC after ASCT failure was associated with a trend to an improved survival when compared with chemotherapy/radiotherapy strategies. The limited number of patients in the alloRIC group may have prevented the demonstration of a significant benefit of this approach. No prospective randomized studies between alloRIC and salvage chemotherapy/radiotherapy have been conducted in HL patients relapsing after ASCT. However, two retrospective studies have been published on this topic, showing the superiority of alloRIC over conventional treatment [3, 17] . In the study by Sarina et al., 185 patients relapsing after ASCT were considered for alloRIC and divided into two groups according to the availability of donor [17] . In univariate and multivariable analyses, the availability of a donor was significant for both progression-free survival and OS.
The results and usefulness of a prognostic factor analysis are limited not only by the selection of the factors as potential candidates for the analysis, but also by the population of patients included into it. One of the potential pitfalls of our analysis is the inevitable selection bias related to a study only involving patients reported to a transplant database and excluding those receiving only palliative care, but the number of patients involved in the analysis is significantly higher to what has been previously reported, and the follow-up is significantly longer (>4 years for the surviving patients).
In conclusion, in the EBMT-GITMO databases, most HL patients with ASCT failure are treated with chemotherapy/ radiotherapy and some of them with a second transplantation. Although the prognosis of these patients remains poor, our results shows that some of them will ultimately have any further successful treatment with long-term survival. The usefulness of our prognostic score to tailor the therapy of subgroups of patients requires its validation in an independent series. Finally, another important challenge for clinicians will be how best to integrate the new therapeutic agents such as brentuximab vedotin or HDAC-inhibitors to direct care for these patients. 
